Compare Kinross Gold Corporation (KGC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Summit Therapeutics Inc — how do they compare? Kinross Gold Corporation trades at $23.45 (market cap $26.63B), while Summit Therapeutics Inc trades at $14.57 (market cap $10.48B). The key difference: Kinross Gold Corporation is far larger — about 2.5× Summit Therapeutics Inc's market cap, and Kinross Gold Corporation pays a 0.64% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KGC | SMMT | |
|---|---|---|
Market Cap | $26.63B | $10.48B |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $29.32 |
52-Week Low | $15.42 | $13.05 |
Enterprise Value | $25.18B | $9.90B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.43, up 3.79% on the day, with strong fundamentals including a P/E of 9.59 and robust profitability metrics. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 results due July 29, 2026. Technical indicators show bearish momentum despite oversold RSI conditions, while analyst consensus remains strongly bullish with a $37.20 price target representing 59% upside potential.
KGC presents a compelling value opportunity with attractive valuation multiples and strong cash flow generation. Key risks include gold price volatility and rising operational costs. The stock's current discount to analyst targets and improving financial trajectory suggest potential for significant appreciation, though investors should monitor Q2 earnings and gold market dynamics closely.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
